First Patient Enrolled in W. L. Gore & Associates, Inc. Septal Occluder Clinical Study for Atrial Septal Defect
10/26/2012 8:01:00 AM
FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates (Gore) today reported the first patient enrolled in the GORE® Septal Occluder Clinical Study evaluating the safety and efficacy of the new GORE Septal Occluder in the treatment of percutaneous, trancatheter closure of ostium secundum atrial septal defect (ASD). The patient was successfully treated at Duke University Medical Center in Durham, North Carolina by John Rhodes, MD, Chief of the Congenital Heart Center; and Mandy Green, FNP-C.
comments powered by